Lytic and mechanical stability of clots composed of fibrin and blood vessel wall components

Z. ROTTENBERGER,* E. KOMOROWICZ,* L. SZABÓ,† A. BÓTA,‡ Z. VARGA,‡ R. MACHOVICH,* C. LONGSTAFF§ and K. KOLEV*

*Laboratory of Experimental Medicine, Semmelweis University; †Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences; ‡Department of Biological Nanochemistry, Institute of Molecular Pharmacology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary; §Biotherapeutics, Haemostasis Section, National Institute for Biological Standards and Control, South Mimms, Potters Bar, UK

To cite this article: Rottenberger Z, Komorowicz E, Szabó L, Bóta A, Varga Z, Machovich R, Longstaff C, Kolev K. Lytic and mechanical stability of clots composed of fibrin and blood vessel wall components. J Thromb Haemost 2013; 11: 529–38.

Summary. Background: Proteases expressed in atherosclerotic plaque lesions generate collagen fragments, release glycosaminoglycans (chondroitin sulfate [CS] and dermatan sulfate [DS]) and expose extracellular matrix (ECM) proteins (e.g. decorin) at sites of fibrin formation. Objective: Here we address the effect of these vessel wall components on the lysis of fibrin by the tissue plasminogen activator (tPA)/plasminogen system and on the mechanical stability of clots. Methods and results: MMP-8-digested collagen fragments, isolated CS, DS, glycosylated decorin and its core protein were used to prepare mixed matrices with fibrin (additives present at a 50-fold lower mass concentration than fibrinogen). Scanning electron microscopy (SEM) showed that the presence of ECM components resulted in a coarse fibrin structure, most pronounced for glycosylated decorin causing an increase in the median fiber diameter from 85 to 187 nm. Rheological measurements indicated that these structural alterations were coupled to decreased shear resistance (1.8-fold lower shear stress needed for gel/fluid transition of the clots containing glycosylated decorin) and rigidity (reduction of the storage modulus from 54.3 to 33.2 Pa). The lytic susceptibility of the modified fibrin structures was increased. The time to 50% lysis by plasmin was reduced approximately 2-fold for all investigated ECM components (apart from the core protein of decorin which produced a moderate reduction of the lysis time by 25%), whereas fibrin-dependent plasminogen activation by tPA was inhibited by up to 30%. Conclusion: ECM components compromise the chemical and mechanical stability of fibrin as a result of changes in its ultrastructure.

Keywords: decorin, fibrin, glycosaminoglycan, plasmin, rheology, shear stress.

Introduction

Fatal outcomes in ischemic cardio- and cerebrovascular disease are not necessarily a consequence of critical narrowing of the atherosclerotic artery; rather rupture or erosion of the plaque provokes formation of unstable thrombi, the detachment of which can occlude downstream branches of the vascular tree (reviewed in [1]). Convincing histopathological data support the notion that such microembolization is the ultimate cause of myocardial necrosis in patients dying of acute coronary thrombosis [2]. Although the mechanisms triggering thrombus formation on atherosclerotic plaques are well characterized, little is known about the factors that determine the stability of these thrombi and thus their capacity to form emboli. Because the solid matrix of thrombi is composed of fibrin that originates from a blood-borne protein (fibrinogen), the molecular events at the interface of blood and damaged vascular wall appear to be crucial with respect to this stability. A major role in plaque disruption is attributed to matrix metalloproteinases (MMP) expressed in the vessel wall (reviewed in [3]). Infiltration of thrombi by leukocytes supplies additional MMPs and serine proteases (e.g. neutrophil elastase) at this interface (reviewed in [4]). We have recently demonstrated that such cell- (MMP8, MMP9, elastase) and thrombus-related (thrombin, plasmin) proteolytic activity results in clearance of the glycosaminoglycans (GAGs) and modification of the extracellular matrix protein (ECM) structure in the arterial wall [5]. Based on these findings, we hypothesized that vascular wall components released through proteolysis...
could modify the stability of the fibrin matrix formed at the thrombus/vessel wall interface. Both mechanical stability and susceptibility to the action of the tissue plasminogen activator (tPA)/plasminogen system may be affected (reviewed in [6]). In the present study we addressed the stability of fibrin matrices co-polymerized in vitro with vascular proteins, or their fragments, and GAG side chains, selected either because of their abundance (type I and III collagens are the major ECM proteins of the arteries [7,8]) or known effects in blood coagulation and fibrinolysis (decorin [9,10], chondroitin sulfate and dermatan sulfate [11]).

Materials and methods

Human fibrinogen (plasminogen free) was the product of Calbiochem (La Jolla, CA, USA). This preparation contained low levels of contaminating factor (F)XIII, the activity of which resulted in depletion of γ-chain monomers in reducing SDS polyacrylamide electrophoresis within 1 h after clotting at the thrombin and CaCl2 concentrations used in these experiments. In the absence of CaCl2 (in the rheological assay), no γ-dimers could be detected within 30 min. The chromogenic substrates for plasmin, Spectrozyme-PL (H-D norleucyl-hexahydrotryosyl-lysine-p-nitroanilide) and for thrombin, Spectrozyme-TH (H-D-hexahydrotryosyl-L-alanyl-L-arginine-p-nitroanilide) were from American Diagnostica (Pfungstadt, Germany), and tPA was from Boehringer Ingelheim (Germany). Bovine thrombin was purchased from Serva (Heidelberg, Germany) and was further purified by ion-exchange chromatography on sulfopropyl-Sepharose yielding a preparation with a specific activity of 2100 IU mg⁻¹ [12]. Dermatan sulfate and chondroitin sulfate were from Sigma-Aldrich Kft. (Budapest, Hungary). Collagen G was from Biochrom AG (Berlin, Germany). Recombinant human decorin core protein was a product of R&D Systems (Abingdon, England). Blood was collected from healthy volunteers with venipuncture in 10 mM trisodium citrate (380°/C) with 0.3–1.2 mM NaCl in buffer D. Fractions were analyzed with acentric blue staining after electrophoresis in polyacrylamide gel (SDS-PAGE). Proteoglycan-containing fractions were pooled and dialyzed overnight at 4°C against 50 mM sodium acetate pH 6.0 buffer containing 7 μM urea, 100 mM NaCl (buffer D). A DEAE-Sepharose column was equilibrated with 10 volumes of buffer D2 and mixed with the dialyzed fractions. After washing the column with 5 column volumes of buffer D2, gradient elution was carried out with 0.3–1.2 mM NaCl in D2. Glycosaminoglycan containing fractions were pooled and dialyzed against 50 mM sodium acetate pH 6.0 buffer containing 1.5 mM ammonium-sulfate (buffer D3) overnight at 4°C. An Octyl-Sepharose column was washed with 10 column volumes of buffer D3, mixed with the proteoglycan-containing dialyzed fractions, washed with 5 column volumes of buffer D3 and eluted with a 1.5–0 mM ammonium-sulfate gradient. Fractions were analyzed after SDS-PAGE with acentric blue staining and anti-decorin antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Decorin-containing fractions were dialyzed in 10 mM HEPES pH 7.4 buffer containing 150 mM NaCl and stored at −20°C. Decorin was verified with mass spectrometric analysis of its trypic peptides on LCQ-Fleet Ion Trap mass spectrometer (Thermo Scientific, Karlsruhe, Germany).

Generation of collagen fragments

Recombinant MMP-8 (R&D Systems) at 1 mg mL⁻¹ in 50 mM HEPES buffer pH 7.5 containing 150 mM NaCl, 1 mM CaCl2 was activated with 1 mM aminophenylmercuric-acetate (APMA) at 37°C for 1 h. Collagen G (50:10% mixture of collagen I and III) was digested with the activated enzyme at 37°C for 8 h (1 mg collagen in 1 mL reaction volume in the same buffer). The process was stopped with 50 mM EDTA pH 8.0. This digestion resulted in collagen fragments in the range of 20–60 kDa as verified with silver staining after SDS-PAGE.

Turbidimetric fibrinolytic assays

In 96-well microtiter plates, 6 μM fibrinogen in 10 mM HEPES buffer pH 7.4 containing 150 mM NaCl, 2 mM CaCl2 and collagen fragments/decorin core protein/aorta decorin/dermatan sulfate/chondroitin sulfate were mixed with 20 nM thrombin and 6 nM plasmin in a total volume of 100 μL. Clot formation and dissolution was followed by measuring the light absorbance at 340 nm at 37°C.
with a Zenyth 200rt microplate spectrophotometer. The lysis time ($t_{1/2}$), defined as the time needed to reduce the turbidity of the clot to a half-maximal value, was used as a quantitative parameter of fibrinolytic activity. In a preliminary series of experiments a range of additive concentrations between 1 and 200 µg mL$^{-1}$ was screened in this assay and the minimal concentrations yielding significant differences in the lysis time were selected for more detailed investigation (2 µg mL$^{-1}$ for the two forms of decorin and 50 µg mL$^{-1}$ for the rest of the additives). In certain cases, plasma containing 50 ng mL$^{-1}$ tPA was clotted with 15 nm thrombin and 12.5 mM CaCl$_2$.

**Scanning electron microscopic studies**

Fibrin clots of 50 µL volume were prepared in duplicate: 6 µm fibrinogen in 10 mM HEPES buffer pH 7.4 containing 150 mM NaCl and 2 mM CaCl$_2$ was clotted with 20 µm thrombin at 37 °C for 1 h, with or without vessel wall proteins/glycosaminoglycans at final concentrations 50 µg mL$^{-1}$ for collagen fragments, dermatan sulfate or chondroitin sulfate and 50 nm for decorin core protein or aorta decorin. Clots were washed repeatedly with 0.5% chondroitin sulfate and 50 nM decorin core protein or 50 nM for decorin. Clots were washed repeatedly with 0.5% Triton X-100 and placed in 100 mM Na-cacodylate pH 7.2 for 1 h. After fixation in 1% glutaraldehyde for 1 h, the samples were dehydrated in a series of ethanol dilutions (20–50–70–85–96%, 5 min each), 1:1 mixture of 96% ethanol:acetone and finally with pure acetone, followed by critical point drying with CO$_2$ in an E3000 Critical Point Drying Apparatus (Quorum Technologies, Newhaven, UK). The samples were mounted on adhesive carbon discs, sputter coated with gold in SC7620 Sputter Coater (Quorum Technologies) and images were taken with scanning electron microscope EVO40 (Carl Zeiss GmbH, Oberkochen, Germany). The scanning electron microscopic (SEM) images were analyzed to determine the diameter of the fibrin fibers using self-designed program functions running under the Image Processing Toolbox v. 8.0 of Matlab 7.14.0.739 (R2012a) (The Mathworks, Natick, MA) as previously described [14].

**Plasminogen activation assay**

In 96-well microtiter plates, 3.3 µm fibrinogen in 10 mM HEPES buffer pH 7.4 containing 150 mM NaCl, 1.5 mM CaCl$_2$, 75 nm plasminogen and vessel wall proteins or glycosaminoglycans (at concentrations given above for the SEM samples) was clotted with 25 nm thrombin in a volume of 80 µL. After 45 min at 37 °C, 60 µL of 14 nm tPA and 0.6 mM Spectrozyme-PL in 10 mM HEPES, 150 mM NaCl pH 7.4 were placed on the surface of the clot. The forming plasmin generated p-nitroaniline, the absorbance of which was continuously recorded at 405 nm ($A_{405}$) with a Zenith 200rt spectrophotometer (Anthos Labtec Instruments GmbH, Salzburg, Austria). The measured values were plotted vs. time squared ($t^2$) yielding a linear relationship according to the equation $\Delta A_{405} = 0.5ek_{cat}[tPA]t^2$ [15], where $e = 12.6$ mm$^{-1}$ cm$^{-1}$ is the extinction coefficient of p-nitroaniline [16], $k_{cat} = 350$ min$^{-1}$ is the turnover number of plasmin on Spectrozyme-PL [16], $k_{cat}$ and $t/PA$ are the catalytic constant for plasminogen activation and the concentration of tPA in the reactive layer on the surface of fibrin, respectively [17]. The term $V_{app} = k_{cat}[tPA]$ is equivalent to the apparent maximal rate of plasminogen activation in the reactive layer of fibrin and was determined from linear regression according to the abovementioned equation (Curve fitting toolbox v. 3.2.1 of Matlab 2012a).

**Evaluation of fibrin rigidity**

Fibrin clot at 7.4 µm in 10 mM HEPES pH 7.4 buffer containing 150 mM NaCl and the investigated ECM components at final concentrations of 50 nm for aorta decorin and decorin core protein or 50 µg mL$^{-1}$ for collagen fragments, dermatan sulfate and chondroitin sulfate was mixed with 10 nm thrombin and 410 µL of the clotting mixture was transferred to the stationary plate of HA-AKE RheoStress 1 oscillation rheometer (Thermo Scientific) thermostatted at 37 °C. The cone (Titanium, 2° angle, 35 mm diameter) of the rheometer was brought to the gap position and shear strain ($\gamma$) of 0.015 was imposed exactly at 2 min after the addition of thrombin. Measurements of storage modulus ($G'$) and loss modulus ($G''$) were taken at 1 Hz in the course of 15 min with HAAKE RheoWin data manager software v. 3.50.0012 (Thermo Scientific) [18]. After this 15-min clotting phase, determination of the flow limit of the fibrin gels was performed on the same samples by increasing the applied shear stress ($\tau$) from 0.01 to 500.0 Pa stepwise in 150 s and measurements of the resulting strain were used for calculation of the viscosity modulus (the critical shear stress $\tau_b$ determined by extrapolation of the fall in viscosity to 0 was used as indicator of the gel/fluid transition in the fibrin structure).

**Confocal microscopic imaging**

Fibrin clots were prepared from 6 µm fibrinogen, 2% of which was Alexa Fluor® 546-conjugated fibrinogen (Invitrogen Life Technologies, Budapest, Hungary) in 10 mM HEPES buffer pH 7.4 containing 150 mM NaCl, 2 mM CaCl$_2$, 1.5 µm plasminogen and the tested additives with 16 nm thrombin for 30 min at room temperature in sterile, uncoated IBIDI VI 0.4 µ-slides (Ibidi GmbH, Martinsried, Germany). Thereafter 4 µg mL$^{-1}$ tPA-YFP (tPA with Yellow Fluorescent Protein fused to its C-terminal expressed using pFastBac-tPA as previously described) [14] was added to the edge of the clot and the fluorescence (excitation wavelength 488 nm, emission wavelength 525 nm for tPA-YFP detection and excitation wavelength 543 nm, emission wavelength 575 nm for Alexa546-fibrinogen detection) was monitored with Confocal Laser Scanning
System LSM710 (Carl Zeiss GmbH) taking sequential images of the fluid-fibrin interface at a distance of approximately 50 μm from the chamber surface with identical exposures and laser intensities using a Plan-NeofluarX10/0.5 objective.

**Statistical analysis**

The distribution of the data on fiber diameter was analyzed according to an algorithm used previously [19]: theoretical distributions were fitted to the empirical data sets and compared using Kuiper test and Monte Carlo simulation procedures. The statistical evaluation of other experimental measurements in this study was performed with the Kolmogorov–Smirnov test (Statistics Toolbox 8.0 of Matlab R2012a).

**Results**

To model the impact of ECM components on the lytic susceptibility of fibrin formed in the immediate vicinity of proteolytically modified blood vessel walls, composite clots were prepared from fibrin and purified proteoglycans or their fragments. In this experimental setting, when clotting and fibrinolysis were initiated simultaneously, the time course of fibrin formation and dissolution reflects the global stability of fibrin clots exposed to plasmin, the major fibrinolytic enzyme. The presence of ECM proteins or glycosaminoglycans at concentration corresponding to only several per cent of the scaffold-forming fibrin concentration resulted in a significantly less stable clot structure, reflected in the shorter lysis time of the composite clots (Fig. 1 and Table 1). The presence of a sugar subunit in the structure of the modifier enhances the lytic susceptibility of the clots, as demonstrated by the difference in the lysis time for clots with full and core decorin, whereas the strongest destabilizing effects were related to the highly negatively charged glycosaminoglycans (chondroitin sulfate and dermatan sulfate). Noteworthy differences were seen in the ascending phase of the turbidity.

![Fig. 1. Fibrin clot lysis assay.](image1)

**Table 1** Clotting and lysis parameters of composite fibrin clots

| Additive     | None     | fDCN     | cDCN     | CF       | DS       | CS       |
|--------------|----------|----------|----------|----------|----------|----------|
| Clotting time (min) | 5.6 ± 0.3 | 2.9 ± 0.1* | 1.1 ± 0.1* | 0.9 ± 0.1* | 5.4 ± 0.1 | 7.1 ± 0.3* |
| Lysis time (min)    | 63.9 ± 8.7 | 34.9 ± 4.4* | 47.6 ± 8.9* | 30.4 ± 12.2* | 25.8 ± 3.1* | 28.0 ± 6.4* |

Clots containing 6 μm fibrin, 6 nM plasmin and the indicated additives were prepared and the values of the clotting and lysis time were determined as the time needed to reach half-maximal turbidity on the ascending and descending part of the turbidity curves illustrated in Fig. 1. The values are reported as mean and standard deviation of at least eight measurements from three independent experiments. fDCN, 50 nM aorta decorin; cDCN, 50 nM decorin core protein; CF, 50 μg mL⁻¹ collagen fragments; DS, 50 μg mL⁻¹ dermatan sulfate; CS, 50 μg mL⁻¹ chondroitin sulfate. *P < 0.05 according to the Kolmogorov–Smirnov test in comparison to pure fibrin.

![Fig. 2. Plasminogen activation on the surface of fibrin.](image2)

© 2012 International Society on Thrombosis and Haemostasis
curves in Fig. 1 indicating accelerated formation of the composite clots containing proteins (shorter time to reach half-maximal turbidity in the presence of collagen fragments, glycosylated or core decorin, Table 1), whereas the isolated glycosaminoglycans either had no effect (dermatan sulfate) or delayed clot formation (chondroitin sulfate). Because a potential mechanism of the observed enhancement in the formation and lysis of the fibrin clots could be a direct effect on the activity of the enzymes involved (thrombin and plasmin), their activity was measured in a fibrin-free system on small peptide substrates for thrombin and plasmin (Spectrozyme-TH and Spectrozyme-PL, respectively). None of the investigated ECM components applied at the concentrations as in Fig. 1 influenced the enzyme activities in the absence of fibrin (data not shown).

In the experimental setup used in Fig. 1, plasmin activity is detected on the same substrate (fibrin) that serves as a cofactor in tPA-dependent plasminogen activation. Thus any effects of changes in fibrin structure on the rates of zymogen activation are complicated by changes in the susceptibility of modified fibrin as a substrate for plasmin. In order to identify the isolated effects on plasminogen activation, plasmin generated on the surface of fibrin was measured using a small peptide substrate (Spectrozyme-PL) that can efficiently compete with fibrin and prevents the digestion of the cofactor (Fig. 2). The apparent maximal plasminogen activation rate ($V_{app}$) decreased to a statistically significant degree in the presence of ECM components; 12–29% reduction in $V_{app}$ could be observed (Table 2). This modest attenuation of plasminogen activation on the surface of fibrin reflects either decreased catalytic turnover ($k_{cat}$) or impaired interfacial penetration ($[tPA]$) in the modified fibrin structure ($V_{app} = k_{cat}[tPA]$). If plasminogen was activated in the absence of fibrin in a two-stage assay [20], the investigated modifiers did not affect the activation rate precluding direct effects on tPA (data not shown). The lack of effects in free solution and the variable inhibition of plasminogen activation on the fibrin surface pointed to a role for the modification of fibrin structure in the reactive interface layer that is known to profoundly affect both tPA and plasminogen binding to fibrin, an essential determinant of plasmin generation in fibrin clots [14,21]. The dynamics of this process was addressed with confocal microscopic studies using fluorescent tPA-YFP (Fig. 3). In all clots, tPA-YFP accumulated in a sharp interfacial layer, which moved as a result of fibrin lysis by the generated plasmin. The rate of migration of this front (Table 2) correlated with the rates of plasmin-mediated fibrin lysis (Fig. 1) rather than with the rate of overall plasmin generation (Fig. 2). The spatial distribution of the fluorescent tPA in the rearranging fibrin structure provides a mechanistic explanation for this effect. One of the modifiers, chondroitin sulfate, resulted in a broader homogenous tPA-rich band in fibrin, whereas in the presence of the other additives tPA co-localized with aggregates of partially degraded fibrin (the coincident green, tPA and red fibrin fluorescence is seen as yellow grains in Fig. 3). A similar granular pattern of tPA accumulation coupled to faster lysis, in spite of slower plasminogen activation has been previously reported for fibrin composed of thick fibers [14], suggesting a significant role for the structure of the fibrin network in these composite clots.

Further structural details underpinning the observed changes in the enzymatic susceptibility and the tPA-cofactor function of the composite fibrin matrices were investigated using SEM (Fig. 4A). Morphometric analysis of the SEM images indicated a significant increase in fiber diameter in all cases when fibrin was polymerized in the presence of protein additives (decorin or collagen fragments). Although the negatively charged chondroitin sulfate and dermatan sulfate did not significantly influence the architecture of the fibrin network individually, fully glycosylated decorin, containing the same sugar subunits, caused the most pronounced modification of fibrin structure (Fig. 4B).

The viscoelastic properties of the composite fibrin clots were approached using rheological methods (Fig. 5). Fully glycosylated decorin exerted the most pronounced effects on the rigidity of fibrin (decrease in the storage modulus $G'$ by about 40%) and its susceptibility to structural rearrangements upon deformation (decrease in the loss modulus $G''$ by about 25%) (Table 3). All other

| Additive | None | tDCN | cDCN | CF | DS | CS |
|----------|------|------|------|----|----|----|
| $V_{app}$ for Fn formation ($\text{nm min}^{-1}$) | 0.18 ± 0.007 | 0.160 ± 0.011* | 0.139 ± 0.008* | 0.130 ± 0.015* | 0.010 ± 0.015* | 0.161 ± 0.011* |
| Relative activation rate of Pg | 1 | 0.87 | 0.87 | 0.76 | 0.71 | 0.82 | 0.88 |
| Relative migration rate of tPA | 1 | 2.03 | 1.52 | 1.54 | 1.54 | 1.46 | 1.56 |

$tPA$ and plasmin substrate Spectrozyme-PL were added to clots containing 3 µm fibrin, 0.1 µm plasminogen and the indicated additives and the values of the apparent activation rate ($V_{app}$) were determined as the slopes of the plots illustrated in the Inset of Fig. 2. The values are reported as mean and standard deviation of at least eight measurements from three independent experiments. The relative migration rate of tPA in lysing fibrin has been calculated from the position of the tPA-YFP-rich layer on the surface of fibrin clots as illustrated in Fig. 3. tDCN, 50 nM glycosylated aorta decorin; cDCN, 50 nM decorin core protein; CF, 50 µg mL$^{-1}$ collagen fragments; DS, 50 µg mL$^{-1}$ dermatan sulfate; CS, 50 µg mL$^{-1}$ chondroitin sulfate. $*P < 0.05$ according to the Kolmogorov–Smirnov test in comparison to pure fibrin.

© 2012 International Society on Thrombosis and Haemostasis
modifiers had no effect on $G'$ and $G''$ values (except for a moderate decrease in $G'$ related to collagen fragments). The only parameter that was significantly decreased by all ECM components (except the core protein of decorin) was the critical shear stress ($\tau_0$) causing an abrupt decline in viscosity of fibrin (gel/fluid transition) (Table 3).

In order to evaluate the validity of the observed effects in a more physiological environment, tPA-mediated lysis of blood plasma clots was examined (Fig. 6). Dermatan sulfate (at $50 \, \mu g \, mL^{-1}$) completely blocked the formation of plasma clots in line with its known potentiating effect on the inactivation of thrombin by heparin cofactor II [22–24]. Plasma clots containing all other components lysed at faster rates following the trend of plasmin-mediated (Fig. 1) and tPA-mediated (Fig. 3) fibrin lysis.

**Discussion**

The in vitro models applied in this study address the question of lytic susceptibility and mechanical stability of fibrin structures formed when products of limited proteolysis are released from the arterial wall and coincide with fibrin polymerization. The concentrations of fibrinogen and the ionic environment used in the present studies correspond to the in vivo conditions found in blood plasma, whereas the vascular wall components (proteins and their fragments or glycosaminoglycans) were present in amounts up to 2.5% by mass of the amount of fibrin. Thus, the effects reported here require minimal exposure of ECM components at the site of thrombus formation, and the concentrations used are reasonable in view of the massive collagen and decorin deposits observed in primary atherosclerotic, as well as in restenotic lesions after coronary angioplasty [25] and the extensive proteolytic modification of the vascular wall induced by leukocytes [5]. At present, in spite of qualitative evidence for significant abundance in atherosclerotic lesions of the ECM components investigated in the current study, there are scarce quantitative data on their concentrations. However, the example of chondroitin sulfate, which is present at $2 \, \mu g \, mL^{-1}$ basal concentration in plasma, but at 2-fold higher concentration when platelets are activated [26], suggests the local concentration could be orders of magnitude higher, before dilution in several liters of circulating blood.

The mechanical stability of fibrin structures that form efficient hemostatic plugs at sites of vessel injury is definitely compromised if ECM components co-polymerize. Significantly lower shear stress is needed to liquefy a fibrin gel in the presence of glycosylated decorin, collagen fragments, dermatan sulfate or chondroitin sulfate ($\tau_0$ in Table 3). The strongest rheological effects are produced by fully glycosylated decorin, which also causes the most pronounced changes in fibrin structure (Fig. 4).
ment with earlier reports [18], thicker fibrin fibers were coupled to increases in the loss tangent parameter ($\tan \delta = G''/G'$) (Table 3). According to the interpretation of rheological parameters suggested in Ref. [18], the loss tangent reflects the dissipation of energy originating from molecular rearrangements in the fibrin network caused by mechanical forces (dissociation of monomers within protofibrils or of protofibrils within fibers). This parameter indicates that in spite of the identical trend of changes (decrease) in the rigidity (storage modulus $G'$) and dissipation energy (loss modulus $G''$) the fibrin structure softened by aorta decorin is relatively more susceptible to rearrangements of fibrin monomers or protofibrils than pure homogeneous fibrin. Rheology studies were performed in the absence of CaCl$_2$, because our fibrinogen preparation contained factor FXIII and, as also shown by others [18], in the presence of physiological concentrations of CaCl$_2$ FXIIIa-dependent cross-linking continues for several hours. Thus, the $G'$, $G''$ values do not reach a plateau by 2 h, in contrast to the situation seen without CaCl$_2$ (Fig. 5). In order to obtain reliable estimates for parameters of the mechanical properties of the clots we chose to perform the rheology measurements in the absence of CaCl$_2$ and FXIIIa-dependent cross-linking. As other techniques used in these studies (light absorbance in turbidimetry, fluorescence intensity in confocal microscopy, fiber diameter in scanning electron microscopy) were not sensitive to cross-linking, physiological concentrations of CaCl$_2$ were included in these systems. In view of recent data that the antifibrinolytic function of FXIII is exclusively expressed through $\alpha_2$-plasmin inhibitor cross-linking [27], the similar pattern of results observed
in assay systems that contain FXIIIa, but no α2-plasmin inhibitor (fibrin clots in Figs. 1 and 3) or both FXIIIa and α2-plasmin inhibitor (plasma clots in Fig. 6) suggests that the reported ECM effects are independent of the function of FXIII in fibrinolysis.

Functional assays were investigated that could discriminate effects in the two stages of the classic fibrinolytic pathway: plasminogen activation by tPA on a fibrin template and fibrin dissolution by plasmin (reviewed in [28]). When plasminogen was activated by tPA applied to the plate and fibrin dissolution by plasmin (reviewed in [28]).

According to our earlier data from identical activation assays [14], thicker fibers are coupled to impaired cofactor function of fibrin in tPA-dependent plasminogen activation. In agreement with this general trend, in the present study, we observed the strongest inhibition of plasminogen activation in fibrin matrices containing collagen fragments and decorin core protein, which caused significant increases in the fiber diameter (Fig. 4). However, by 25–30% (Table 2), whereas the presence of glycosaminoglycans (either in free form or attached to decorin) moderated this effect to 12–18% inhibition. Because none of the investigated modifiers affected plasminogen activation in the absence of fibrin (data not shown), the observed effects could be explained by modulation of the interfacial phenomena on the surface of the composite clots. According to our earlier data from identical activation assays [14], thicker fibers are coupled to impaired cofactor function of fibrin in tPA-dependent plasminogen activation. In agreement with this general trend, in the present study, we observed the strongest inhibition of plasminogen activation in fibrin matrices containing collagen fragments and decorin core protein, which caused significant increases in the fiber diameter (Fig. 4). However,

Table 3 Viscoelasticity parameters of composite fibrin clots

| Additive    | None | fDCN | cDCN | CF | DS | CS |
|-------------|------|------|------|----|----|----|
| G’ (Pa)     | 54.29 ± 12.98 | 33.20 ± 3.68* | 47.04 ± 0.62 | 40.70 ± 2.88* | 41.13 ± 10.68 | 47.81 ± 9.20 |
| G’′/G’     | 4.58 ± 0.90 | 3.38 ± 0.50* | 4.07 ± 0.43 | 3.83 ± 0.38 | 3.77 ± 0.65 | 4.45 ± 0.74 |
| G’′/G’     | 0.086 ± 0.015 | 0.102 ± 0.006* | 0.086 ± 0.008 | 0.094 ± 0.008 | 0.093 ± 0.007 | 0.094 ± 0.006 |
| τ₀ (Pa)     | 154.42 ± 24.34 | 85.58 ± 10.65* | 130.25 ± 7.85 | 95.56 ± 9.40* | 103.89 ± 8.50* | 111.01 ± 15.81* |

Clots containing 7.3 μm fibrin and the indicated additives were prepared and their rigidity was evaluated in an oscillation rheometer. The values of the storage modulus (G’), the loss modulus (G’′) and the loss tangent (tanθ = G’′/G’) are shown for the 15th min of clotting, when they reached a plateau, whereas the critical shear stress τ₀ was determined by extrapolation of the fall in viscosity to 0 as illustrated in Fig. 5B. Mean and standard deviation of at least three measurements are shown. fDCN, 50 nm glycosylated aorta decorin; cDCN, 50 nm decorin core protein; CF, 50 μg mL⁻¹ collagen fragments; DS, 50 μg mL⁻¹ dermatan sulfate; CS, 50 μg mL⁻¹ chondroitin sulfate. *P < 0.05 according to the Kolmogorov–Smirnov test in comparison to additive-free clot lysis time.
the thickness of fibrin observed in the presence of fully glycosylated decorin protein and collagen fragments. Further studies involving different types of modifiers, such as decorin core protein, aorta decorin, collagen fragments or isolated glycosaminoglycans, are required to investigate the quantity and nature of the fibrinogen substrate. For example, in the literature [30,31] and proteolytic destruction [3] and additional studies are required to investigate the quantity and nature of the protein and glycosaminoglycan modulators in thrombi attached to, or derived from, atherosclerotic plaques.

Acknowledgements

This work was supported by the Hungarian Scientific Research Fund [OTKA 75430, 83023] and the Wellcome Trust [083174/B/07/Z]. The authors are grateful to G. Oravec and K. Holti for their technical assistance.

Disclosure of Conflict of Interests

The authors state that they have no conflict of interest.
References

1 Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res 2009; 50(Suppl): S352–7.

2 Schwartz RS, Burke A, Farb A, Kaye D, Lesser JR, Henry TD, Virmani R. Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death: relation to epicardial plaque histopathology. J Am Coll Cardiol 2009; 54: 2167–73.

3 Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherosclerosis: the good, the bad, and the ugly. Circ Res 2002; 90: 251–62.

4 Wohner N. Role of cellular elements in thrombus formation and dissolution. Cardiovasc Hematol Agents Med Chem 2008; 6: 224–8.

5 Wohner N, Keresztes Z, Sotonyi P, Szabol C, Komorowicz E, Machovich R, Kolev K. Neutrophil granulocyte-dependent proteolysis enhances platelet adhesion to the arterial wall under high-shear flow. J Thromb Haemost 2010; 8: 1624–31.

6 Weisel JW, Litvinov RI. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 2008; 6: 161–80.

7 Morton LF, Barnes MJ. Collagen polymorphism in the normal and diseased blood vessel wall. Investigation of collagens types I, III and V. Atherosclerosis 1982; 42: 41–51.

8 Murata K, Motayama T, Kotake C. Collagen types in various layers of the human aorta and their changes with the atherosclerotic process. Atherosclerosis 1986; 60: 251–62.

9 Dugan TA, Yang VW, McQuillan DJ, Höök M. Decorin binds fibrinogen in a Zn2+-dependent interaction. J Biol Chem 2003; 278: 13655–62.

10 Dugan TA, Yang VW, McQuillan DJ, Höök M. Decorin modulates fibrin assembly and structure. J Biol Chem 2006; 281: 38208–16.

11 Homma R, Mase A, Toida T, Kashiwagi I, Igarashi K. Modulation of blood coagulation and fibrinolysis by polyanines in the presence of glycosaminoglycans. Int J Biochem Cell Biol 2005; 37: 1911–20.

12 Lundblad RL, Kingdon HS, Mann KG. Thrombin. Methods Enzymol 1976; 45: 156–76.

13 Choi HU, Johnson TL, Pal S, Tang LH, Rosenberg L, Neame PJ. Characterization of the dermatan sulfate proteoglycans, DS-PGI and DS-PGII, from bovine articular cartilage and skin isolated by octyl-sepharose chromatography. J Biol Chem 1989; 264: 2876–84.

14 Longstaff C, Thelwell C, Williams SC, Silva MM, Szabol L, Kolev K. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011; 117: 661–8.

15 Ränby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704: 461–9.

16 Tanko-Salamon A, Tenekeciyev K, Machovich R, Kolev K. Suppressed catalytic efficiency of plasmin in the presence of long-chain fatty acids. Identification of kinetic parameters from continuous enzymatic assay with Monte Carlo simulation. FEBS J 2008; 275: 1274–82.

17 Longstaff C, Whitton CM. A proposed reference method for plasminogen activators that enables calculation of enzyme activities in Si units. J Thromb Haemost 2004; 2: 1416–21.

18 Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77: 2813–26.

19 Varjú I, Sotonyi P, Machovich R, Szabol L, Tenekeciyev K, Silva MM, Longstaff C, Kolev K. Hindered dissolution of fibrin formed under mechanical stress. J Thromb Haemost 2011; 9: 979–86.

20 Kolev K, Owen WG, Machovich R. Dual effect of synthetic plasmin substrates on plasminogen activation. Biochim Biophys Acta 1995; 1247: 239–45.

21 Silva MM, Thelwell C, Williams SC, Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue plasminogen activator (tPA). J Thromb Haemost 2012; 10: 2354–60.

22 Pavão MS, Aiello KR, Werneck CC, Silva LC, Valente AP, Mulloy B, Colwell NS, Tollefsen DM, Mourão PA. Highly sulfated dermatan sulfates from Ascidians. Structure versus anticoagulant activity of these glycosaminoglycans. J Biol Chem 1998; 273: 27848–57.

23 Liaw PC, Becker DL, Stafford AR, Fredenburgh JC, Weitz JI. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 2001; 276: 20959–65.

24 Verhamme IM, Bock PE, Jackson CM. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II. J Biol Chem 2004; 279: 9785–95.

25 Riesen R, Isner JM, Blessing E, Loushín C, Nikol S, Wight TN. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 1994; 144: 962–74.

26 Hamad OA, Ekdahl KN, Nilsson PH, Andersson J, Magotti P, Lambirs JD, Nilsson B. Complement activation triggered by the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 2006; 167: 1405–15.

27 Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through α2-antiplasmin cross-linking. Blood 2011; 117: 6371–4.

28 Kolev K, Longstaff C, Machovich R. Fibrinolysis at the fluid-solid interface of thrombi. Curr Med Chem Cardiovasc Hematol Agents Med Chem 2008; 6: 1413–21.

29 Saito A, Munakata H. Analysis of plasma proteins that bind to glycosaminoglycans. Biochim Biophys Acta 2007; 1770: 241–6.

30 Wagner WD. Proteoglycan structure and function as related to atherosclerosis. Ann N Y Acad Sci 1985; 454: 52–68.

31 Shirk RA, Parthasarathy N, San Antonio JD, Church FC, Wagner WD. Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J Biol Chem 2000; 275: 18085–92.